Interações de Cloreto de potássio

Potassium chloride is contraindicated in patients on triamterene and amiloride. (bula de Cloreto de potássio, Contraindicações)

Solid dosage forms of potassium chlorides have produced stenotic and/or ulcerative lesions of the small bowel and deaths. (bula de Citrato de potássio, Advertências e precauções)

…with: • type 2 diabetes with microalbuminuria, • serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions… (bula de Eplerenona, Contraindicações)

Information for patients Patients who receive spironolactone and hydrochlorothiazide tablets should be advised to avoid potassium supplements and foods containing high levels of potassium including salt substitutes. (bula de Espironolactona + hidroclorotiazida, Precauções)

• GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride : Concomitant use is not recommended. (bula de Glicopirrônio, Interações medicamentosas)

Potassium chloride is contraindicated in patients on triamterene and amiloride. (bula de Cloreto de potássio, Contraindicações)

Potassium chloride is contraindicated in patients on triamterene and amiloride. (bula de Cloreto de potássio, Contraindicações)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.3 )] , NSAIDs, or potassium supplements or potassium sparing diuretics. (bula de Alisquireno, Advertências e precauções)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. (bula de Anlodipino + benazepril, Advertências e precauções)

…Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart… (bula de Anlodipino + valsartana, Interações medicamentosas)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (bula de Benazepril, Advertências e precauções)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (bula de Candesartana, Interações medicamentosas)

Co-administration of candesartan cilexetil and hydrochlorothiazide tablets with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (bula de Candesartana + hidroclorotiazida, Interações medicamentosas)

Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. (bula de Captopril, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet. (bula de Ciclosporina, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions ( 7.3 )]. (bula de Enalapril, Advertências e precauções)

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (bula de Enalapril + hidroclorotiazida, Interações medicamentosas)

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (bula de Enalaprilate, Interações medicamentosas)

This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (bula de Espironolactona, Advertências e precauções)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Monitor serum potassium levels; use potassium supplements if necessary. (bula de Fludrocortisona, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. (bula de Fosinopril, Interações medicamentosas)

Drug Interactions Potassium supplements and potassium-sparing diuretics As noted above (“Derangements of Serum Electrolytes”), the net effect of fosinopril sodium and hydrochlorothiazide may be to elevate a patient’s serum potassium, to reduce it, or to leave it unchanged. (bula de Fosinopril + hidroclorotiazida, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (bula de Iodeto de potássio, Interações medicamentosas)

Coadministration of AVALIDE with potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia, sometimes severe. (bula de Irbesartana + hidroclorotiazida, Advertências e precauções)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (bula de Lisinopril, Advertências e precauções)

Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (bula de Lisinopril + hidroclorotiazida, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Potassium Supplements and Potassium-Sparing Diuretics: Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. (bula de Moexipril, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.3) ] . (bula de Olmesartana, Advertências e precauções)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus and the concomitant use of agents such as potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.2) ] . (bula de Perindopril, Advertências e precauções)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)] . (bula de Sacubitril + valsartana, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Hyperkalemia Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (bula de Telmisartana, Advertências e precauções)

Hyperkalemia Telmisartan Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (bula de Telmisartana + anlodipino, Advertências e precauções)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (bula de Cloreto de potássio, Interações medicamentosas)

Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. (bula de Trandolapril, Interações medicamentosas)

Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7.1 ) (bula de Valsartana, Interações medicamentosas)

…Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart… (bula de Valsartana + hidroclorotiazida, Interações medicamentosas)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (bula de Cloreto de potássio, Interações medicamentosas)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (bula de Cloreto de potássio, Interações medicamentosas)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (bula de Cloreto de potássio, Interações medicamentosas)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (bula de Cloreto de potássio, Interações medicamentosas)

Supplemental potassium and/or spironolactone may prevent hypokalemia and metabolic alkalosis in these patients. (bula de Bumetanida, Advertências)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (bula de Cloreto de potássio, Interações medicamentosas)

Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. (bula de Dobutamina, Interações medicamentosas)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (bula de Cloreto de potássio, Interações medicamentosas)

Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride. (bula de Hiosciamina, Interações medicamentosas)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (bula de Cloreto de potássio, Interações medicamentosas)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (bula de Cloreto de potássio, Interações medicamentosas)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (bula de Cloreto de potássio, Interações medicamentosas)

…been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (bula de Milrinona, Interações medicamentosas)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (bula de Cloreto de potássio, Interações medicamentosas)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (bula de Cloreto de potássio, Interações medicamentosas)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (bula de Cloreto de potássio, Interações medicamentosas)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (bula de Cloreto de potássio, Interações medicamentosas)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (bula de Cloreto de potássio, Interações medicamentosas)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (bula de Cloreto de potássio, Interações medicamentosas)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (bula de Cloreto de potássio, Interações medicamentosas)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (bula de Cloreto de potássio, Interações medicamentosas)